332
Views
35
CrossRef citations to date
0
Altmetric
Research Article

Magnetic catechin–dextran conjugate as targeted therapeutic for pancreatic tumour cells

, , , , , , & show all
Pages 408-415 | Received 30 Aug 2013, Accepted 22 Dec 2013, Published online: 16 Jan 2014
 

Abstract

Background: Catechin–dextran conjugates have recently attracted a lot of attention due to their anticancer activity against a range of cancer cells. Magnetic nanoparticles have the ability to concentrate therapeutically important drugs due to their magnetic-spatial control and provide opportunities for targeted drug delivery.

Purpose: Enhancement of the anticancer efficiency of catechin–dextran conjugate by functionalisation with magnetic iron oxide nanoparticles.

Methods: Modification of the coating shell of commercial magnetic nanoparticles (Endorem) composed of dextran with the catechin–dextran conjugate.

Results: Catechin–dextran conjugated with Endorem (Endo–Cat) increased the intracellular concentration of the drug and it induced apoptosis in 98% of pancreatic tumour cells placed under magnetic field.

Discussion: The conjugation of catechin–dextran with Endorem enhances the anticancer activity of this drug and provides a new strategy for targeted drug delivery on tumour cells driven by magnetic field.

Conclusion: The ability to spatially control the delivery of the catechin–dextran by magnetic field makes it a promising agent for further application in cancer therapy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.